129 related articles for article (PubMed ID: 2516611)
1. Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis.
Tomson CR; Channon SM; Ward MK; Laker MF
Nephrol Dial Transplant; 1989; 4(9):792-9. PubMed ID: 2516611
[TBL] [Abstract][Full Text] [Related]
2. Plasma oxalate in patients receiving continuous ambulatory peritoneal dialysis.
Tomson CR; Channon SM; Parkinson IS; Owen JP; Ward MK; Simpson JM; Laker MF
Nephrol Dial Transplant; 1988; 3(3):295-9. PubMed ID: 3140104
[TBL] [Abstract][Full Text] [Related]
3. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.
Morgan SH; Maher ER; Purkiss P; Watts RW; Curtis JR
Nephrol Dial Transplant; 1988; 3(1):28-32. PubMed ID: 3132636
[TBL] [Abstract][Full Text] [Related]
4. Oxalate retention in chronic renal failure: tubular vs glomerular diseases.
Tomson CR; Channon SM; Ward MK; Laker MF
Clin Nephrol; 1989 Aug; 32(2):87-95. PubMed ID: 2788548
[TBL] [Abstract][Full Text] [Related]
5. Oxalate clearance by haemodialysis--a comparison of seven dialysers.
Franssen CF
Nephrol Dial Transplant; 2005 Sep; 20(9):1916-21. PubMed ID: 15998647
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).
Yamauchi A; Fujii M; Shirai D; Mikami H; Okada A; Imai E; Ando A; Orita Y; Kamada T
Clin Nephrol; 1986 Apr; 25(4):181-5. PubMed ID: 3698351
[TBL] [Abstract][Full Text] [Related]
7. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
Elgstoen KB; Johnsen LF; Woldseth B; Morkrid L; Hartmann A
Nephrol Dial Transplant; 2010 Jul; 25(7):2341-5. PubMed ID: 20167571
[TBL] [Abstract][Full Text] [Related]
8. Oxalic acid concentration in serum measured by isotopic clearance technique. Experience in hyper- and normo-oxaluric subjects.
Prenen JA; Mees EJ; Boer P; Endeman HJ; Ephraim KH
Proc Eur Dial Transplant Assoc; 1979; 16():566-70. PubMed ID: 549000
[TBL] [Abstract][Full Text] [Related]
9. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
10. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
Ono K
Clin Nephrol; 1986 Nov; 26(5):239-43. PubMed ID: 3802587
[TBL] [Abstract][Full Text] [Related]
11. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure.
Watts RW; Veall N; Purkiss P
Clin Sci (Lond); 1984 May; 66(5):591-7. PubMed ID: 6368103
[TBL] [Abstract][Full Text] [Related]
12. [Diurnal variation in plasma oxalate concentration and oxalate clearance in calcium oxalate stone formers with special reference to the effect of oxalate loading].
Kinoshita N
Hinyokika Kiyo; 1987 Sep; 33(9):1331-41. PubMed ID: 3434488
[TBL] [Abstract][Full Text] [Related]
13. [Plasma oxalate concentration in calcium oxalate stone formers].
Hoshina A
Hinyokika Kiyo; 1984 Oct; 30(10):1405-15. PubMed ID: 6524552
[TBL] [Abstract][Full Text] [Related]
14. [Plasma glycolate concentrations under conditions of dialysis].
Balcke P; Schmidt P; Zazgornik J; Kopsa H; Haubenstock A
Wien Klin Wochenschr; 1983 Sep; 95(18):656-8. PubMed ID: 6649652
[TBL] [Abstract][Full Text] [Related]
15. [Secondary oxalosis in chronic renal insufficiency].
Balcke P; Schmidt P; Zazgornik J; Kopsa H; Deutsch E
Z Urol Nephrol; 1982 Jun; 75(6):409-14. PubMed ID: 7124142
[TBL] [Abstract][Full Text] [Related]
16. [Factors which influence phosphorus removal in hemodialysis].
Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
[TBL] [Abstract][Full Text] [Related]
18. Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria.
Marangella M; Cosseddu D; Petrarulo M; Vitale C; Linari F
Nephrol Dial Transplant; 1993; 8(12):1333-7. PubMed ID: 8159301
[TBL] [Abstract][Full Text] [Related]
19. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
